(RTTNews) - Mesoblast Limited (MESO, MSB.AX) reported that its loss attributable to the owners of the company for fiscal year ended June 30, 2025 widened to US102.14 million from last year's US$87.96 million. But net loss per share narrowed to 8.46 US cents from 8.91 US cents in the prior year.
Annual total revenues from cell therapy products were US$17.2 million, up 191% on prior year. Revenue growth driven by successful launch of Ryoncil in the final quarter.
MESO closed Thursday's regular trading at $15.95 down $0.17 or 1.05%. In the after-hours trading the stock further dropped $1.75 or 10.97%.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
